Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Deloitte
Moodys
Federal Trade Commission
Medtronic
Boehringer Ingelheim
Accenture
Chinese Patent Office
Merck

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202067

« Back to Dashboard

NDA 202067 describes ONFI, which is a drug marketed by Lundbeck Pharms Llc and is included in two NDAs. It is available from one supplier. Additional details are available on the ONFI profile page.

The generic ingredient in ONFI is clobazam. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the clobazam profile page.
Summary for 202067
Tradename:ONFI
Applicant:Lundbeck Pharms Llc
Ingredient:clobazam
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 202067
Ingredient-typeBenzodiazepines
Mechanism of ActionCytochrome P450 2D6 Inhibitors
Suppliers and Packaging for NDA: 202067
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ONFI clobazam TABLET;ORAL 202067 NDA Lundbeck Pharmaceuticals LLC 67386-314 N 67386-314-01
ONFI clobazam TABLET;ORAL 202067 NDA Lundbeck Pharmaceuticals LLC 67386-315 N 67386-315-01

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength5MG
Approval Date:Oct 21, 2011TE:RLD:No
Regulatory Exclusivity Expiration:Oct 21, 2018
Regulatory Exclusivity Use:ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Oct 21, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 21, 2018
Regulatory Exclusivity Use:ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Oct 21, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 21, 2018
Regulatory Exclusivity Use:ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
US Department of Justice
AstraZeneca
Medtronic
Boehringer Ingelheim
Fuji
UBS
QuintilesIMS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.